Three Alston Bird attorneys urge companies regulated by FDA to engage with the agency on issues involving artificial intelligence and machine learning.
Federal Register notice: FDA withdraws the approval of 23 NDAs from multiple applicants because they are no longer marketed.
Three Alston Bird attorneys urge companies regulated by FDA to engage with the agency on issues involving artificial intelligence and machine learning.
Federal Register notice: FDA withdraws the approval of 23 NDAs from multiple applicants because they are no longer marketed.
FDA warns Royal Philips about Quality System and Medical Device Reporting violations at its medical device manufacturing facility in Suzhou, China.
Federal Register notice: FDA makes available its annual report entitled “Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments” for fiscal year 2022.
